Insiders who reported open-market trades in the last 12 months at the companies G. Walmsley Graham files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
David C. Myles - $3.11M in OLMA purchases and sales in the last 12 months
G. Walmsley Graham is a corporate insider of Olema Pharmaceuticals, Inc. (OLMA). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did G. Walmsley Graham last file a Form 4?
The most recent primary Form 4 on record is dated 23 June 2026, one of 4 filings going back to 2024.
Has G. Walmsley Graham been buying or selling stock?
Recorded transactions: 1 open-market purchase ($4.73M) and 1 open-market sale ($4.73M) across all tracked filings.
G. Walmsley Graham files SEC Form 4 reports at Olema Pharmaceuticals, Inc. (OLMA). 4 SEC Form 4 filings on record going back to 2024, most recently on 23 June 2026. Most recent open-market trade: bought $4.73M of OLMA on 18 December 2024. Lifetime open-market purchases: $4.73M. Lifetime open-market sales: $4.73M.
Recent transactions
10
The latest 10 SEC Form 4 transactions reported by G. Walmsley Graham.
InsiderAlpha's records for G. Walmsley Graham go back to 2024: 4 primary Form 4 filings, an average of 1.3 per year. The typical open-market purchase is $4.73M (1 buy totaling $4.73M). The largest single buy on record is $4.73M of OLMA in 2024. Sales side: 1 recorded sale totaling $4.73M, so the filing history runs sell-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
